Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMBRELLA B: Extension study of atezolizumab-based therapy
2018-003352-20Phase 4Active
- Sponsor
- Roche
- Start
- Dec 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of atezolizumab in Non-hematologic malignancy, non-small cell lung cancer (NSCLC) and cancer, sponsored by Roche. Primary endpoint: Clinical benefit on continued therapy. Started Dec 2018; status: active.
02
Drugs
atezolizumab
03
Conditions
Non-hematologic malignancynon-small cell lung cancer (NSCLC)cancer
Beyond the preview
Go deeper on 2018-003352-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003352-20.